Aims Statistically significant positive correlations are reported for the abundance of hepatic
drug‐metabolizing enzymes. We investigate, as an example, the impact of CYP3A4 …

Introduction: Pharmacogenetics-informed drug prescribing is increasingly applied in clinical
practice. Typically, drug metabolizing phenotypes are determined based on genetic test …

What is known and objective Esomeprazole, the S‐isomer of omeprazole, is a proton pump
inhibitor which has been approved by over 125 countries, also known as NEXIUM® …

The creation of virtual populations allows the estimation of pharmacokinetic parameters,
such as metabolic clearance in extreme individuals rather than the 'average human' …

Quantifying variability in pharmacokinetics (PK) and toxicokinetics (TK) provides a science-
based approach to refine uncertainty factors (UFs) for chemical risk assessment. In this …

Omeprazole is an established probe drug to assess cytochrome P450 (CYP) 2C19 activity
(phenotyping). Because it has nonlinear pharmacokinetics (PK) after oral administration …

The aim of this study was to evaluate the relationship between polymorphisms in CYP2C19
and the single‐dose pharmacokinetics (PKs) of omeprazole in healthy Chinese volunteers …

The beta-blocker metoprolol (the sixth most commonly prescribed drug in the USA in 2017)
is subject to considerable drug–gene interaction (DGI) effects caused by genetic variations …

This study aimed to develop a joint population pharmacokinetic model for an antipsychotic
agent in development (S33138) and its active metabolite (S35424) produced by reversible …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• The only existing study of CYP2C19*
17‐associated alterations in drug pharmacokinetics was retrospective and compared probe …